Original Article

Intravenous Thrombolysis Attenuates Neurologic Deterioration After Ischemic Stroke

Authors: James E. Siegler, MD, Sheryl Martin-Schild, MD, PhD

Abstract

Introduction: Although intravenous tissue plasminogen activator (IV tPA) is associated with neurologic deterioration (ND) caused by hemorrhage, whether it attenuates deterioration as a result of other etiologies including progressive stroke remains unexplored. The objective of this study was to determine whether IV tPA is associated with a reduced risk of ND caused by progressive stroke.

Methods: A retrospective investigation of consecutively admitted patients with acute ischemic stroke (July 2008–June 2014) within 4.5 hours of symptom onset was conducted at a tertiary care center. Patients treated with IV tPA were compared with those who were not. The primary outcome was ND resulting from progressive infarction (a two-point increase in the National Institutes of Health Stroke Scale score during a 24-hour period).

Results: A total of 699 registry patients (median age 65 years, interquartile range 55–76, 48.4% women, 70.4% nonwhite) were included in the study, and 58.1% received IV tPA. In crude regression, IV tPA did not reduce the odds of ND caused by progressive infarction; however, IV tPA–treated patients were at a 55% lower odds of ND from any cause (odds ratio 0.45, 95% confidence interval 0.32–0.61, P < 0.001). After adjusting for covariates, IV tPA use remained strongly associated with a 39% lower odds of ND from any cause (odds ratio 0.61, 95% confidence interval 0.48–0.79, P < 0.001).

Conclusions: Although IV tPA did not correlate with a reduced odds of progressive infarction, it was significantly associated with a lower odds of ND by any mechanism.

 

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Siegler JE, Martin-Schild S. Early neurological deterioration (END) after stroke: the END depends on the definition. Int J Stroke 2011;6:211-212.
 
2. Roquer J, Rodriguez-Campello A, Gomis M, et al. Acute stroke unit care and early neurological deterioration in ischemic stroke. J Neurol 2008;255:1012-1017.
 
3. Kwan J, Hand P. Early neurological deterioration in acute stroke: clinical characteristics and impact on outcome. QJM 2006;99:625-633.
 
4. Adams HP, Jr Davis PH, Leira EC, et al. Baseline NIH Stroke Scale score strongly predicts outcome after stroke: a report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology 1999;53:126-131.
 
5. Siegler JE, Boehme AK, Kumar AD, et al. Identification of modifiable and nonmodifiable risk factors for neurologic deterioration after acute ischemic stroke. J Stroke Cerebrovasc Dis 2013;22:e207-e213.
 
6. Weimar C, Mieck T, Buchthal J, et al. Neurologic worsening during the acute phase of ischemic stroke. Arch Neurol 2005;62:393-397.
 
7. Castillo J, Leira R, Garcia MM, et al. Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome. Stroke 2004;35:520-526.
 
8. Ogata T, Yasaka M, Wakugawa Y, et al. Predisposing factors for acute deterioration of minor ischemic stroke. J Neurol Sci 2009;287:147-150.
 
9. Seet RC, Zhang Y, Wijdicks EF, et al. Relationship between chronic atrial fibrillation and worse outcomes in stroke patients after intravenous thrombolysis. Arch Neurol 2011;68:1454-1458.
 
10. Audebert HJ, Rott MM, Eck T, et al. Systemic inflammatory response depends on initial stroke severity but is attenuated by successful thrombolysis. Stroke 2004;35:2128-2133.
 
11. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
 
12. IST-3 Collaborative Group., Sandercock P, Wardlaw JM, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the Third International Stroke Trial <IST-3]): a randomised controlled trial. Lancet 2012;379:2352-2363.
 
13. Hemmen TM, Ernstrom K, Raman R. Two-hour improvement of patients in the National Institute of Neurological Disorders and Stroke trials and prediction of final outcome. Stroke 2011;42:3163-3167.
 
14. Yeo LL, Paliwal P, Teoh HL, et al. Early and continuous neurologic improvements after intravenous thrombolysis are strong predictors of favorable long-term outcomes in acute ischemic stroke. J Stroke Cerebrovasc Dis 2013;22:e590-e596.
 
15. Muresan IP, Favrole P, Levy P, et al. Very early neurologic improvement after intravenous thrombolysis. Arch Neurol 2010;67:1323-1328.
 
16. Siegler JE, Boehme AK, Dorsey AM, et al. A comprehensive stroke center patient registry: advantages, limitations, and lessons learned. Med Stud Res J 2013;2:21-29.
 
17. Adams HP, Jr Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
 
18. Siegler JE, Martin-Schild S. Daily National Institutes of Health Stroke Scale examinations at stroke centers: why not do them? Int J Stroke 2015;10:140-142.
 
19. Siegler JE, Boehme AK, Kumar AD, et al. What change in the National Institutes of Health Stroke Scale should define neurologic deterioration in acute ischemic stroke? J Stroke Cerebrovasc Dis 2013;22:675-682.
 
20. Grotta JC, Welch KM, Fagan SC, et al. Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial. Stroke 2001;32:661-668.
 
21. Toyoda K, Fujimoto S, Kamouchi M, et al. Acute blood pressure levels and neurological deterioration in different subtypes of ischemic stroke. Stroke 2009;40:2585-2588.
 
22. Wahlgren N, Ahmed N, D&#x00E1valos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007;369:275-282.
 
23. Alexandrov AV, Felberg RA, Demchuk AM, et al. Deterioration following spontaneous improvement: sonographic findings in patients with acutely resolving symptoms of cerebral ischemia. Stroke 2000;31:915-919.
 
24. Siegler JE, Boehme AK, Albright KC, et al. A proposal for the classification of etiologies of neurologic deterioration after acute ischemic stroke. J Stroke Cerebrovasc Dis 2013;22:e549-e556.
 
25. van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-607.
 
26. Machumpurath B, Davis SM, Yan B. Rapid neurological recovery after intravenous tissue plasminogen activator in stroke: prognostic factors and outcome. Cerebrovasc Dis 2011;31:278-283.
 
27. Felberg RA, Okon NJ, El-Mitwalli A, et al. Early dramatic recovery during intravenous tissue plasminogen activator infusion: clinical pattern and outcome in acute middle cerebral artery stroke. Stroke 2002;33:1301-1307.
 
28. Blinzler C, Breuer L, Huttner HB, et al. Characteristics and outcome of patients with early complete neurological recovery after thrombolysis for acute ischemic stroke. Cerebrovasc Dis 2011;31:185-190.
 
29. Saposnik G, Young B, Silver B, et al. Lack of improvement in patients with acute stroke after treatment with thrombolytic therapy: predictors and association with outcome. JAMA 2004;292:1839-1844.
 
30. Lansberg MG, Thijs VN, Bammer R, et al. Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke. Stroke 2007;38:2275-2278.
 
31. Nakajima M, Hirano T, Naritomi H, et al. Symptom progression or fluctuation in transient ischemic attack patients predicts subsequent stroke. Cerebrovasc Dis 2010;29:221-227.
 
32. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-1025.
 
33. Nacu A, Bringeland GH, Khanevski A, et al. Early neurological worsening in acute ischaemic stroke patients. Acta Neurol Scand 2016;133:25-29.
 
34. Hwang YH, Seo JG, Lee HW, et al. Early neurological deterioration following intravenous recombinant tissue plasminogen activator therapy in patients with acute lacunar stroke. Cerebrovasc Dis 2008;26:355-359.
 
35. Siegler JE, Samai A, Semmes E, et al. Early neurologic deterioration after stroke depends on vascular territory and stroke etiology. J Stroke 2016;18:203-210.
 
36. Yamamoto H, Bogousslavsky J, van Melle G. Different predictors of neurological worsening in different causes of stroke. Arch Neurol 1998;55:481-486.
 
37. Davalos A, Toni D, Iweins F, et al. Neurological deterioration in acute ischemic stroke: potential predictors and associated factors in the European cooperative acute stroke study (ECASS) I. Stroke 1999;30:2631-2636.
 
38. Mori M, Naganuma M, Okada Y, et al. Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry. Cerebrovasc Dis 2012;34:140-146.
 
39. Siegler JE, Albright KC, George AJ, et al. Time to neurological deterioration in ischemic stroke. Med Stud Res J 2016. In press.
 
40. Siegler JE. The utility of quantifiable neurologic assessments after stroke: in response to Marsh et al,"The NIH Stroke Scale has limited utility in accurate daily monitoring of neurologic status.". Neurohospitalist 2016;6:95-96.
 
41. Liao Y, Greenlund KJ, Croft JB, et al. Factors explaining excess stroke prevalence in the US Stroke Belt. Stroke 2009;40:3336-3341.
 
42. Kleindorfer D, Lindsell CJ, Brass L, et al. National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke 2008;39:924-928.
 
43. Bambauer KZ, Johnston SC, Bambauer DE, et al. Reasons why few patients with acute stroke receive tissue plasminogen activator. Arch Neurol 2006;63:661-664.